Equities research analysts expect Cue Biopharma Inc (NASDAQ:CUE) to announce ($0.44) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Cue Biopharma’s earnings. Cue Biopharma reported earnings of ($0.62) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 29%. The company is expected to report its next quarterly earnings report on Tuesday, November 12th.
On average, analysts expect that Cue Biopharma will report full year earnings of ($1.96) per share for the current fiscal year. For the next year, analysts forecast that the company will post earnings of ($1.35) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Cue Biopharma.
Cue Biopharma (NASDAQ:CUE) last announced its earnings results on Thursday, August 8th. The company reported ($0.46) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.10. Cue Biopharma had a negative net margin of 2,039.41% and a negative return on equity of 151.93%. The business had revenue of $1.06 million during the quarter.
CUE stock traded up $0.02 during midday trading on Thursday, reaching $8.82. 100,500 shares of the company’s stock traded hands, compared to its average volume of 86,567. Cue Biopharma has a 52-week low of $4.16 and a 52-week high of $9.94. The stock has a market cap of $185.61 million, a P/E ratio of -4.54 and a beta of 1.19. The company has a current ratio of 2.65, a quick ratio of 2.65 and a debt-to-equity ratio of 0.19. The stock’s 50-day moving average is $8.13 and its 200 day moving average is $8.02.
Hedge funds have recently made changes to their positions in the business. BNP Paribas Arbitrage SA increased its holdings in Cue Biopharma by 1,159.9% during the first quarter. BNP Paribas Arbitrage SA now owns 3,805 shares of the company’s stock valued at $29,000 after buying an additional 3,503 shares during the last quarter. Strs Ohio boosted its position in shares of Cue Biopharma by 500.0% in the second quarter. Strs Ohio now owns 15,000 shares of the company’s stock worth $134,000 after purchasing an additional 12,500 shares during the period. Sigma Planning Corp bought a new position in shares of Cue Biopharma in the first quarter worth approximately $325,000. Rock Creek Group LP bought a new position in shares of Cue Biopharma in the second quarter worth approximately $447,000. Finally, Northern Trust Corp boosted its position in shares of Cue Biopharma by 2.0% in the second quarter. Northern Trust Corp now owns 204,555 shares of the company’s stock worth $1,839,000 after purchasing an additional 3,970 shares during the period. 19.93% of the stock is owned by institutional investors and hedge funds.
About Cue Biopharma
Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.
Featured Story: CBOE Russell 2000® Volatility Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.